Bibliografía
BIBLIOGRAFÍA
1. Font J, Pallares L, Cervera R y col: Systemic lupus erythematosus in the elderly. Ann Rheum. Dis. 1992; 50:702-5.
3. Goch DV, Verna M: Nefropatía Lúpica. Revisión. Revista de postgrado de la VIa Cátedra de Medicina 2003; 125(3):7-9.
5. Braunwald E, Isselbacher K, Harrison Ky col: "Principios de Medicina Interna" 13ª ed. 1995; Vol. II: 1502-04.
6. Sanz-Guajardo D, Botella J. Nefropatia lupica. Rev Port Nefropatia e Hipertension 1996; 9 (2):103-40.
7. Schaller, JG: Systemic Lupus Erythematosus. En: Nelson textbook of Pediatrics Bherman RE, Kliegman RM, Arvin AM. eds. 15th ed. Philadelphia: WB. Saunders: 1996:673-6.
8. Adler Sh. G., Cohen A.H., Glassock R.J: Secondary Glomerular Diseases En: The Kidney 5th ed.Barry M.Brenner (ed) Philadelphia, W.B.Saunders 1996:1498-1516.
9. Appel G, Rishnam JR: Secondary glomerular disease, en “Breneer & Rector´s.The Kidney, 6a ed, BM Breneer(editor). Phyladelfia, Saunders, 2000: 1350-1448.
10. Espinosa D, Florin J,Benitez MC, Alvarez CZ, Lirola E: Correlación clínico –histológica de la nefritis lúpica. Rev. Cubana de Pediatr. 2000; 72(2):112-19.
12. Madaio MP: B cells and autoantiboides in the pathogenesis of lupus nephritis. Inmunol Res 1998; 17:123-32.
13. Takiguchi M, Murakami M, Nakagawa I, y col: CTLA 41gG gene delivery prevents autoantibody production and lupus nephritis in MRL/1pr mice. Life Sci (England), 2000; 66(11):991-1001.
14. Du H, Chen M, Zhang Y, Zhao MH: Characterization of anti-mesangial cell antibodies and their target antigens in patients with lupus nephritis. J Clin Immunol 2005; 25(3):281-7.
15. Beers M, Berkow R: "El Manual Merk". 10ª ed., 1999:428-32.
16. Tan EM, Cohen AS, Fries JF y col: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25:1271-7.
17. Wallace DJ: The Clinical presentation of systemic lupus erythematosus,im Dubois. Lupus Eryhtematosus 6th Ed (vol 1) edited by Hahn BH, Philadelphia, Lippincott William & Wilkins, 2002:621-628.
18. Gordillo Paniagua G: Glomerulopatía del lupus eritemetoso sistémico. En: Nefrología Pediátrica. Mexico: Mosby / Doymar; 1996:222-31.
19. Cervera R, Khamashta M, Font J y col: Morbidity and mortality en systemic lupus erythematosus during a 5-year period. Medicine (Baltimore) 1999; 78:167-75.
20. Rosner S, Ginzler M, Diamond S y col: A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. 1992; 25:612-7.
21. Black RM: Lupus Nephitis: Clinical problems in neprology. 1era ed Philadelphia:Rose and black; 1996:340-52.
22. Registro de Glomerulonefritis. Sociedad Española de Nefrología. Epidemiología de las nefropatías en España. Nefrología XVII: 1997:195-205.
23. Yamada A: Lupus Nephritis: Patogénesis , pathophysiology and therapy. Nippon Rinsho 2006; 64(2):442-5.
24. Berden J. Lupus Nephritis. Kidney Int 1997;52:538-58
25. Boumpas DT, Furie R, Manzi S, Wallace DJ: Advances in Lupus nephritis. Artritis Rheum 2003; 48:719-27.
26. Lewis EJ, Schwartz MM: Pathology of lupus nephritis. Lupus 2005; 14(1):31-8.
27. Moroni G, Trendelemburg M, Del Papa N y col: Anti –C1q antibodies may help in diagnosing a renal flare in Lupus nephitis.Am J Kid Dis 2001; 31:490-98.
28. Makino H, Sugiyama H, Yamasaki Y y col: Glomerular cell apoptosis in human lupus nephritis. Virchow Arch 2003; 443(1):67-77.
29. Stuart L, Hughes J: Apoptosis and autoimmunity. Nephol Dial Transpl 2002; 17:697-700.
30. Balow J: Lupus nephritis: natural history, prognosis and treatment. Clinics in immunology and allergy 1986; 6:353–66.
31. Wlimer WA, Rovin Bh, Herbert CJ y col: Management of glomerular proteinuria. A commentary J.Am Soc Nephrol 2003; 14:3217-32,.
32. Balow J, Austin H: Renal disease in systemic lupus erythematosus. Rheumatic disease clinics of North America 1988; 14:117–33.
33. Balow JE: Clinical presentation and monitoring of lupus nephitis. Lupus. 2005, 14:25-30.Abstract.
34. Brenner and Rector: The Kidney 4a. Ed. Philadelphia. WB Sanders Company. 1996:1369-1429.
35. Ferluga D, Jerse M Vizjak A, Hvala A, Rozman B, Kos-Golja M, Bren AF: Correlation among WHO classed, histomorphologic patterns of glomerulonephitis and glomerular immune deposits in SLE. Wien Klin Wochenschr 2000; 112:692-701.
36. Cameron S: Lupus Nephritis. J Am Soc Nephrol 1999; 10:413-24.
37. Kim S.H., Jeong H. J: Lupus nephitis. Yonsei Med. J.Feb.2003.; 44(1):75-80.
38. Ponticelli C, Moroni G: Renal biopsy in lupus nephritis, what for, when and how often? Nephrol Dial Transplant, 1998; 13:2452.
39. Churg J, Sobin LH: Lupus nephritis in renal disease: Classification and atlas of glomerular disease. New York, Igaku-Shoin 1982; 127-49.
40. Churg J, Bernstein J, Glassock R: Renal disease: Classification and atlas of glomerular disease. Second Edition, New York, Igaku-Shoin 1995:151-79.
41. Broijn J, Verburgh C, Huizinga T: Classifying lupus nephritis: A 32-years-old woman with systemic lupus erythematosus and nephritis syndrome. Am J Kidney Dis 2001; 37:653-7.
42. Case record of the Massachussetts General Hospital: Rapidly progressive renal failure in a 35-year old woman with SLE. N Engl J Med 2001; 344:1152-8.
43. Austin HA, Muenz LR, Joyce KM y col: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 1983; 75:382-91.
44. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE: Diffuse proliferative lupus nephritis; identification of specific pathologic features affecting renal outcome Kidney Int 1984; 25:689-95.
45. Schwartz MM, Lan SP, Berosteein J y col: Irreproducibility of activity and chronicity indices limits their utility in the management of lupus nephritis. Am J Kidney Dis 1993; 21:374-7.
46. Austin HA, Boompas DT, Vaughan EM, Balow JE: Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45:544-50.
47. Lenz O, Contreras G: Treatment options for severe lupus nephritis. Arch Immunol Ther Exp (Warsz) (Poland), Sep-Oct 2004; 52(5):356-65.
48. Wang LC, Yang YH, Lu MY y col ; Retrospective analysis of the renal outcome of pediatric lupus nephritis. Clin Rheumatol (Belgium), Aug 2004; 23(4):318-23.
49. Schwartz MM: The Holy Grail: Pathological indices in lupus nephitis. Kidney Int. 2000; 58:1354-5.
50. Chan TM: Preventing renal failure in patients with severe lupus nephitis. Kidney Int. Suppl.2005; 94:116-119.Abstract.
51. Castañeda R, Esquivel J: Nefritis Lúpica. Revisión. Med Univ 2003; 3:161-168.
52. Pollak VE, Pirani C, Schwartz FD: The natural history of the renal manifestations of systemic lupus erythematosus. J Lab Clin Med. 1964; 63:537-50.
53. Baldwin DS, Lowenstein J, Rothfield NJ y col:The clinical course of proliferative and membranous forms of lupus nephritis. Ann Intern Med. 1970; 73:929-42.
54. Baldwin DS, Gluck MC, Lowenstein J y col. Lupus ne`iritis: Clinical course as related to morphologic forms and their transitions. Am J Med.1977; 62:12-30.
55. McCluskey RT. Lupus nephritis, in Kidney Pathology Decennial 1966-1975, edited by Sommers SC, East Norwalk, CT, Appleton-Century-Crofts.1975:435-50.
56. Appel GB, Silva FG, Pirani CL. Renal involvement in SLE: A study of 56 patients emphasizing histologic classification. Medicine.1978; 75:371-410.
57. Najafi CC, Korbet SM, Lewis EJ y col. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 39:2156-63.
58. Weening JJ, D’Agati V, Schwartz MM y col: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kydney International 2004; 65:521-30.
59. Hill GS, Delahouse M, Nochy D y col: A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000; 58:1160-73.
60. Howie AJ, Turhan N, Adu D: Powerful morphometric indicator of prognosis in lupus nephritis. QJM 2003; 96(6):411-20.
61. Schwartz MM, Kawala KS, Corwin HL, Lewis EJ: The prognosis of segmental glomerulonephritis in systemic lupus erythematosus. Kidney Int 1987; 32:274-79.
62. Mittal B, Hurwitz S, Rennke H, Singh AK: New subcategories of class IV lupus nephritis: are the clinical, histologic and outcome differences. Am J Kidney Dis 2004; 44(6):1050-9.
63. Appel G, Cohen D, Pirani C y col: Long-term follow-up of patients with lupus nephritis. A study based in the classification of the World Health Organization. Am J Med 1987; 83:877-885.
64. Magil A, Puterman M, Ballon S y col: Prognostic factors in diffuse proliferative lupus glomerulonephritis. Kidney Int 1988; 34:511-7.
65. Jerue J, Jurcic V, Vizjak A, Hvala A, Ferluga D: Tubulointersticial involvement in lupus nephitis with emphasis on pathogenesis. Wien Klin Wochenschr 2000; 112: 702-6.
66. Austin HA, Illei GG: Membranous lupus nephritis. Lupus 2005 ; 14(1) :65-71.
67. Pasquali SA, Banfi G, Zucheli A y col : Lupus membranous nephropathy: long term outcome. Clin Nephrol, 1993;39:175-82
68. Sloan RP, Schwartz M, Korbet SM y col: Long outcome in systemic lupus erythematosus membranous glomerulonephritis. J Am Soc Nephrol 1996; 7:299-305.cCune WJ, Saluja M, Bhat S y col: Correlation of membranous glomerular ultrastructural changes with disease severity and outcome in lupus patients initiating cyclophosphamide therapy. Lupus 2005; 14(6):426-33.
69. Jennette JC, Iskander SS, Dalldorf FG: Pathologic differentiation between lupus and non lupus membranous glomerulophathy. Kidney Int 1983; 24:377-89.
70. Austin HA, Vaughan EM, Boumpas DT y col: Lupus membranous nephropathy: controlled trial of prednisone, pulse cyclophosphamide and cyclosporine. A. J Am Soc Nephrol 2000, 11:439.
71. Houssiau FA: Cyclophosphamide in lupus nephritis. Lupus.2005; 14:53-58. Abstract.
72. Ginzler EM, Aranow C: Mycophenolate mofetil in lupus nephritis. Lupus.2005; 14:59-64. Abstract.
73. Hejaili FF, Moist LM, Clark WF: Treatment of lupus nephritis. Drug 2003;63(3):257-74.
74. Luna LG: Manual of histologic staining methods of the Armed Forces Institute of Pathology. American Registry of Pathology. 3ª Ed. New York. Mc Graw-Hill Book Company 1968:36-8.
75. Herrera GA. The value of electron microscopy in the diagnosis and clinical management of lupus nephritis. Ultrastruct Pathol.1999; 23:63-77.
76. González. Técnicas de Microscopía Electrónica en Biología Iª ed. Madrid: Talleres, Selecciones Gráficas. 1969.
77. Reynolds ES. The use of lead citrate at high pH as an electron opaque satin in electronic microscopy. J Cell Bio 1963; 17:108.
78. Spurr A.A low viscosity epoxy resin embedding médium for electrón microscopy. J. Ultraestruct.Res. 1969; 26:31-43.
79. Levy M, Montes de Oca M, Babron MC. Indidence du lupus erythemateux dissémié de 1 enfant en région parisience.press Med 1989; 18 :2022.
80. Ongajyooth L,Shayakul C y col. Lupus nephritis in males: 8 year experience at Siriraj Hospital Thailand. Asian Pac J Allerg Inmunol 1994; 12(3): 87-93.
81. Lea JP. Lupus nephritis in African Americans. Am J Med Sci. 2002; 323(2):85-9.
82. Hunter MG, Hurwitz S, y col. Quantitative morphometry of lupus nephritis: the significance of collage tubular space and inflammatory infiltrate. Kidney Int 2005; 67(1):94-102.
83. Dimitrios S, Tsakas S, Sotsiou F y col. Urinary Transforming Growth Factor-Beta 1 as a Marker of response to immunosuppressive Treatment in patients with Crescentic Nephritis. BCM Nephrol 2006; 6:65-67.
84. Globus J, Mc Cone J. Lupus Nephritis: classification, prognosis, inmunopathogenesis and treatment. Rheum Dis Clin North Am 1994; 20(1):213-42.
85. Ravinal RC, Costa RS, Coimbra TM y col. Mast cell, TGF-betal and myofibroblast expresión in lupus nephritis outcome. Lupus. 2005; 14(10):814-21.
|